Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal Pain

Completed · Phase 2

Conditions studied: Crohn's Disease, Abdominal Pain

In brief

The purpose of this randomized, open-label, parallel, phase 2a study is to determine the tolerability, pharmacokinetics, and efficacy of olorinab in participants with Crohn's disease experiencing abdominal pain.

Key facts

Study ID

NCT03155945

Run by

Arena Pharmaceuticals

People needed

14

Starts

2017-07-19

Expected to finish

2018-09-10

Last updated by the study team

2021-11-02

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Clinical Research of Brandon — Brandon, Florida, United States
• Northwestern University — Chicago, Illinois, United States
• University of Michigan Medical Center — Ann Arbor, Michigan, United States
• Hassman Research Institute — Berlin, New Jersey, United States
• Wake Research Associates — Raleigh, North Carolina, United States
• University of Cincinnati Medical Center — Cincinnati, Ohio, United States
• MultiCare Institute for Research and Innovation — Tacoma, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.